Ocrelizumab biosimilar (Polpharma Biologics)

N/A

Report date: 2024/07/02 16:38:19

Base Information

Drug NameOcrelizumab biosimilar (Polpharma Biologics)

Drug Alias NamePB-018

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsMultiple Sclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryPoland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPolpharma Biologics Sa

China Registration ClassN/A

Develop Information

Active CompaniesPolpharma Biologics Sa

Inactive CompaniesN/A

Active IndicationsMultiple Sclerosis

Inactive IndicationsN/A

Other Information

ATC CodeN/A